

Active Cancer Projects of Potential BD-STEP Fellow Mentors

Title	Funding	PI	Co-Investigators
Personalized Life Expectancy Estimates to Encourage High Value Prostate Cancer Care for Veterans Treated in the Veterans Health Administration	VA HSR&D	Leppert	Wagner
A multi-modal, physician-centered intervention to improve guideline concordant prostate cancer imaging	VA HSR&D	Makarov	Leppert
Opioid CHOICE Pain Management Project	VA HSR&D	Lorenz	
Value of End-of-Life Cancer Care	VA HSR&D	Gidwani	Wagner, Lorenz, Asch
Can Concurrent Hospice Care and Cancer Treatment Achieve Superior Outcomes?	VA HSR&D	Mor	Wagner, Lorenz, Gidwani
Discovery of Predictive Biomarkers for Cancer Therapies Using Synthetic Lethality	NCI	Sinha	Das
Centers of Cancer Nanotechnology Excellence for Translational Diagnostics	NIH	Ghambir	Brooks
Stanford Cancer Development Program in Omics of Lung Diseases	NIH	Rabinovitch	Snyder
Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney Cancer	NIH/NCI	Giaccia, Rankin	Leppert
Active Surveillance and Patient Reported Outcomes in a Diverse Population of Prostate Cancer Patients	NIH/NCI	Gomez	Leppert, Brooks
Biomarkers and clinical parameters associated with Gleason score upgrading	NIH/NCI		Brooks (site PI)
Utilizing Electronic Health Records to Measure and Improve Prostate Cancer	NIH/NCI	Hernandez-Boussard	Brooks
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma	NIH/NCI	Peehl, Kurhanowics	Brooks
The Role of Hypoxia in the Tumor Microenvironment: Implications for Ovarian Cancer Therapy	Army	Rankin	Dorigo
Towards Automating Discovery: Systematic Data Analysis of Science Repositories	DARPA	Mallick, Gil	
IQGAP1 Scaffold-Kinase Interaction Blockade in Renal Cell Carcinoma: A Novel Biomarker and Therapeutic Strategy	DoD	Leppert	Brooks
68Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging	DoD	Iagaru	Brooks
Fusion genes predict prostate cancer recurrence	DoD	Luo, Jarrad, Brooks	

Title	Funding	PI	Co-Investigators
Hypoxic signaling in tumor metastasis: molecular mechanisms and targeted therapy	Mary Kay Ash Charitable Foundation	Rankin	Dorigo
Re-establishing immunotherapy as a first-line treatment for select metastatic renal cell carcinoma patients informed by multiplexed imaging cytometry	Parker Institute for Cancer Immunotherapy	Leppert, Fantl	
Pioneering Perioperative Palliative Care for Surgical Oncology Patients	PCORI	Aslakson	Morris
Machine Learning Classifiers for Automated Staging of Prostate Cancer Patients	Stanford / AstraZeneca	Hernandez-Boussard	
Stanford Molecular and Cellular Characterization Laboratory	Stanford	Brooks	Mallick
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovarian Cancer	Acerta Pharma	Dorigo	
A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer	Adaptimmune, LTD	Dorigo	
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Aduro Biotech, Inc.	Dorigo	
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies	Astra Zeneca	Dorigo	
A Phase III, Randomised, Double-Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy	Astra Zeneca, Gynecological Oncology Group	Dorigo	
A phase III Randomized, Multicenter, Safety and Efficacy Study to Evaluate Nab-paclitaxel as Maintenance Treatment after Induction with Nab-paclitaxel plus Carboplatin in Subjects with Squamous Non-Small Cell Lung Cancer	Celgene Corporation	Das	
A multi-modal approach to discover novel blood based biomarkers for early detection of poor prognosis prostate cancer	CRUK/Cambridge Canary Center Award	Gnanapragasam, Stoyanova	Brooks

Title	Funding	PI	Co-Investigators
A Phase 1b study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epcadostat (INCB024360) in Patients with Recurrent Ovarian Cancer	Immunovaccine, Inc.	Dorigo	
Prospective collection of samples to enable the validation of circulating DNA biomarkers for the early detection of ovarian cancer	Natera, Inc.	Ford	Dorigo
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)	Pharma Mar, S.A.	Dorigo	
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer	TESARO, Inc.	Berek	Dorigo

Note: BD-STEP faculty names in bold

Last updated: February 2018